Filing Flows › Lineage Cell Therapeutics (LCTX) › Q4 2024
Lineage Cell Therapeutics (LCTX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 10, 2025
Lineage Cell Therapeutics (LCTX) reported revenue of $2.9M for the fourth quarter 2024 (Q4 2024), +37% from a year earlier and -24% from the quarter before. Operating margin was -178.2%, net loss $3.2M (113.3% of revenue).
Lineage Cell Therapeutics, Q4 2024: revenue $2.9M (+37% year over year), operating margin -178.2%, net loss $3.2M, operating cash flow −$6.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.9M | -24% | +37% |
| Operating profit | −$5.1M | — | — |
| Net earnings | −$3.2M | — | — |
| Operating cash flow | −$6.3M | — | — |
What changed
Revenue was $2.9M in Q4 2024, up 37% year over year and down 24% from the previous quarter. Collaboration Revenues was the largest line at 86% of revenue.
Operating costs exceeded revenue by $5.1M, an operating margin of -178.2%. The quarter ended with a net loss of $3.2M, wider than the previous quarter's $3.0M loss. Non-operating items added $1.9M, -57% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$6.3M. Non-cash charges added back $151K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items used $4.6M. Capital expenditures of $365K exceeded it, leaving free cash flow of −$6.7M.
Questions
What was Lineage Cell Therapeutics' revenue in the fourth quarter 2024?
Lineage Cell Therapeutics (LCTX) reported revenue of $2.9M for the fourth quarter 2024 (Q4 2024), +37% from a year earlier and -24% from the quarter before.
Was Lineage Cell Therapeutics profitable in the fourth quarter 2024?
Operating loss was $5.1M (-178.2% of revenue) and net loss $3.2M.